PT - JOURNAL ARTICLE AU - Sandra P Smieszek AU - Bartlomiej Przychodzen AU - Sarah E Welsh AU - Jennifer Brzezynski AU - Alyssa Kaden AU - Michael Mohrman AU - Jingyuan Wang AU - Changfu Xiao AU - Sonja Ständer AU - Gunther Birznieks AU - Christos Polymeropoulos AU - Mihael H Polymeropoulos TI - “Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale based endotypes in atopic dermatitis” AID - 10.1101/2020.04.16.20058677 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.16.20058677 4099 - http://medrxiv.org/content/early/2020/04/26/2020.04.16.20058677.short 4100 - http://medrxiv.org/content/early/2020/04/26/2020.04.16.20058677.full AB - Background Atopic dermatitis (AD) is a heritable and heterogeneous inflammatory chronic skin disorder. Utilizing decision tree/supervised learning of extensive clinical, molecular and genetic data, we aimed to define distinct AD endotypes.Methods Deep phenotyping and whole-genome sequencing was performed on samples obtained from participants of EPIONE, a randomized-controlled phase III study in AD patients with severe pruritus comprising mild (23%), moderate (64%) and severe (13%) AD as determined by AD Investigator Global Assessment scale. Three categories of analysis were performed: clinical associations, lab value associations (EOS, IgE, cytokines) and genetic analysis of whole-genome sequencing dataResults Based on a decision tree, we found that five clinical features from the SCORing Atopic Dermatitis (SCORAD) Index can accurately differentiate between IGA severities. We observe a significant difference between severity and eosinophil counts (p<0.001), IgE (p<0.001) and Filaggrin (FLG) LOF frequency (OR 2.3, CI 1.6-3.2, p<0.0001) as well as interleukin pathway genes, specifically IL5RA variants differentiating the groups.Conclusion Our results suggest significant differences between severity groups across a number of features appear to constitute distinct endotypes with likely distinct causative factors. Differing underlying pathophysiology’s indicate endotype knowledge is critical to help guide therapeutic approaches to AD.Capsule summaryAD is a heritable and heterogeneous skin disorder that makes the ‘one size fits all’ therapeutic approach suboptimal for patients with AD.We attempted to define AD endotypes based on clinical, molecular, and genetic characteristics. Clinical, CBC, and genetic associations all tend to suggest existence of separate endotypes.Competing Interest StatementThe authors are employees of Vanda Pharmaceuticals Inc.Clinical TrialClinicalTrials.gov Identifier: NCT03568331Funding StatementResearch funded by Vanda Pharmaceuticals Inc.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon requestADAtopic DermatitisEDCEpidermal Differentiation ComplexEOSEosinophilsFLGFilaggrinIGAInvestigator’s Global AssessmentILInterleukinLOFLoss-of-FunctionNK1RNeurokinin-1 ReceptorCORADSCORing Atopic DermatitisSPSubstance PvIGA-ADValidated Investigator Global Assessment for Atopic Dermatitis